Published in Am J Hematol on March 11, 2014
Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One (2014) 1.43
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica (2014) 1.14
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia (2014) 1.07
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. Leukemia (2014) 0.88
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. J Korean Med Sci (2015) 0.79
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis. Ann Lab Med (2016) 0.75
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia. Indian J Hematol Blood Transfus (2016) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 4.60
The myeloproliferative disorders. N Engl J Med (2006) 4.30
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood (2013) 2.77
Transcriptional regulation of the stem cell leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci. Genome Res (2002) 2.77
Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood (2009) 2.77
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica (2008) 2.46
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J (2002) 2.40
Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol (2010) 2.32
Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood (2004) 2.30
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. Proc Natl Acad Sci U S A (2007) 2.15
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood (2009) 2.11
Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A (2002) 2.08
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood (2006) 2.08
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood (2005) 1.91
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Haematologica (2007) 1.83
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. PLoS Biol (2013) 1.82
Analysis of multiple genomic sequence alignments: a web resource, online tools, and lessons learned from analysis of mammalian SCL loci. Genome Res (2004) 1.80
Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell (2010) 1.78
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood (2012) 1.77
How I treat essential thrombocythemia. Blood (2010) 1.75
DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol (2007) 1.66
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol (2014) 1.65
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood (2011) 1.63
Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood (2008) 1.59
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis. Blood (2004) 1.58
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood (2011) 1.56
Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 1.54
Janus kinase deregulation in leukemia and lymphoma. Immunity (2012) 1.52
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol (2007) 1.52
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood (2012) 1.52
Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica (2007) 1.51
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res (2011) 1.50
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol (2009) 1.48
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood (2012) 1.48
EZH2 mutational status predicts poor survival in myelofibrosis. Blood (2011) 1.45
Genome-wide identification of cis-regulatory sequences controlling blood and endothelial development. Hum Mol Genet (2005) 1.43
Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother (2011) 1.43
Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol (2007) 1.42
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leuk Lymphoma (2014) 1.41
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells (2006) 1.41
Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol (2008) 1.40
Thrombosis in primary myelofibrosis: incidence and risk factors. Blood (2009) 1.37
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
The SCL transcriptional network and BMP signaling pathway interact to regulate RUNX1 activity. Proc Natl Acad Sci U S A (2007) 1.36
The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood (2006) 1.35
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood (2011) 1.34
The transcription factors Scl and Lmo2 act together during development of the hemangioblast in zebrafish. Blood (2006) 1.34
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood (2008) 1.33
Endoglin expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the promoter and a -8-kb enhancer. Blood (2006) 1.32
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells (2008) 1.30
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol (2010) 1.29
Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood (2005) 1.26
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood (2011) 1.26
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2010) 1.25
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Br J Haematol (2012) 1.23
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica (2010) 1.22
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer (2014) 1.22
The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5' bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1. Mol Cell Biol (2004) 1.22
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica (2008) 1.21
Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol (2003) 1.20
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19
Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol (2012) 1.19
Masked polycythemia vera (mPV): results of an international study. Am J Hematol (2013) 1.19
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood (2013) 1.18
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol (2009) 1.18
Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica (2008) 1.18